Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Relapsed/Refractory Acute Myeloblastic Leukemia(AML) by Infusion of Donor High Dose Allogeneic Mismatched Hematopoietic Stem Cells After Chemotherapy

NCT03080922 is registered in ClinicalTrials.gov with The Affiliated Hospital of the Chinese Academy of Military Medical Sciences as lead sponsor.

NCT NCT03080922
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03080922 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Relapsed/Refractory Acute Myeloblastic Leukemia(AML) by Infusion of Donor High Dose Allogeneic Mismatched Hematopoietic Stem Cells After Chemotherapy
Lead sponsor
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Phase
Phase 1/2
Overall status
Unknown status
Start date
March 31, 2016
Completion date
March 31, 2019
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, myeloid